gms | German Medical Science

77. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

24.05. - 28.05.2006, Mannheim

Hyperfractionated accelerated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma

Meeting Abstract

  • corresponding author presenting/speaker Markus Fischer - Department of Oto-Rhino-Laryngology, Essen, Germany
  • Christoph Pöttgen - Department of Radiotherapy, Essen, Germany
  • Silke Wechsler - Department of Oto-Rhino-Laryngology, Essen, Germany
  • Martin Stuschke - Department of Radiotherapy, Essen, Germany
  • Klaus Jahnke - Department of Oto-Rhino-Laryngology, Essen, Germany

German Society of Otorhinolaryngology, Head and Neck Surgery. 77th Annual Meeting of the German Society of Otorhinolaryngology, Head and Neck Surgery. Mannheim, 24.-28.05.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06hno066

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hno2006/06hno066.shtml

Veröffentlicht: 7. September 2006

© 2006 Fischer et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: The excellent results of hyperfractionated and accelerated radiotherapy with concurrent chemotherapy in locally advanced oropharyngeal and hypopharyngeal carcinomas lead to the investigation of this therapeutic regime in nasopharyngeal carcinomas as well.

Methods: 39 patients with nasopharyngeal carcinomas in stage III and IV received accelerated hyperfractionated radiotherapy with concurrent chemotherapy (5-FU, mitomycin C and leucovorin). Primary tumour and regional lymph nodes received 5 x 2 Gy/fr/week during the first three weeks. Thereafter the treatment was accelerated with two daily fractions of 1.4 Gy to a total dose of 72 Gy.

Results: The overall response rate was 100%. The mean follow-up period was 76.2 months. In ten patients salvage surgery of the lymph nodes was performed revealing vital tumour in six cases. The 5 years-overall survival rate was 70+/-8%.

Conclusion: The hyperfractionated accelerated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinomas is effective and feasible.